Literature DB >> 8363380

Biliary excretion of cefixime: assessment in patients provided with T-tube drainage.

J F Westphal1, F Jehl, M Schloegel, H Monteil, J M Brogard.   

Abstract

The biliary excretion profile of cefixime was studied in 10 patients provided with T-tube drainage of the common bile duct after cholecystectomy. Following a single 200-mg oral dose, the peak concentration of cefixime in bile reached 56.9 +/- 70 mg/liter, approximately 20 times as high as the peak concentration in serum, 2.3 +/- 0.85 mg/liter. Cefixime levels in bile proved relatively sustained, since a concentration of 4.3 +/- 3.7 mg/liter was still found 20 h after dosing. The cumulative amount of cefixime recovered in the 24-h bile drainage averaged 10.0 +/- 12.3 mg, which is 5% of the administered dose and positions this beta-lactam antibiotic among the most highly bile-excreted cephalosporins. The presented results show that a single 200-mg oral dose of cefixime provided drug levels in bile consistently higher than the MICs for the most frequently recovered members of the family Enterobacteriaceae in biliary tract infections and maintained these levels for over 20 h after dosing. Accordingly, this cephalosporin deserves further clinical trials to assess its usefulness in both prophylaxis and treatment of biliary tract infections.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8363380      PMCID: PMC187999          DOI: 10.1128/AAC.37.7.1488

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  High-performance liquid chromatography of antibiotics.

Authors:  F Jehl; C Gallion; H Monteil
Journal:  J Chromatogr       Date:  1990-10-12

2.  Anaerobes in human biliary tracts.

Authors:  D M England; J E Rosenblatt
Journal:  J Clin Microbiol       Date:  1977-11       Impact factor: 5.948

3.  Phase I study of cefixime, a new oral cephalosporin.

Authors:  M Nakashima; T Uematsu; Y Takiguchi; M Kanamaru
Journal:  J Clin Pharmacol       Date:  1987 May-Jun       Impact factor: 3.126

4.  The bacteriology of the obstructed biliary tree.

Authors:  A C Maddocks; G R Hilson; R Taylor
Journal:  Ann R Coll Surg Engl       Date:  1973-05       Impact factor: 1.891

5.  beta-Lactam pharmacology in liver disease.

Authors:  J D Turnidge; W A Craig
Journal:  J Antimicrob Chemother       Date:  1983-06       Impact factor: 5.790

6.  Evidence for the existence of a common transport system of beta-lactam antibiotics in isolated rat hepatocytes.

Authors:  I Tamai; T Terasaki; A Tsuji
Journal:  J Antibiot (Tokyo)       Date:  1985-12       Impact factor: 2.649

7.  Biliary bacteria: significance and alterations after antibiotic therapy.

Authors:  H A Pitt; R G Postier; J L Cameron
Journal:  Arch Surg       Date:  1982-04

8.  Antibiotics in biliary disease: the relative importance of antibiotic concentrations in the bile and serum.

Authors:  M R Keighley; R B Drysdale; A H Quoraishi; D W Burdon; J Alexander-Willians
Journal:  Gut       Date:  1976-07       Impact factor: 23.059

9.  Comparative in vitro activity of the new oral cephalosporin cefixime.

Authors:  G W Counts; L K Baugher; B K Ulness; D J Hamilton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-06       Impact factor: 3.267

10.  Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

View more
  3 in total

1.  Assessment of biliary excretion of piperacillin-tazobactam in humans.

Authors:  J F Westphal; J M Brogard; F Caro-Sampara; M Adloff; J F Blicklé; H Monteil; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Effects of surgery on the pharmacokinetic parameters of drugs.

Authors:  J M Kennedy; A M Riji
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

Review 3.  Role of cephalosporins in the era of Clostridium difficile infection.

Authors:  Mark H Wilcox; James D Chalmers; Carl E Nord; Jane Freeman; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2016-09-22       Impact factor: 5.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.